Europe — EMA
Onivyde Pegylated Liposomal (Irinotecan)
Irinotecan, the active ingredient in Onivyde, is a topoisomerase I inhibitor presented as a liposomal formulation for intravenous use.
Request sourcing
What is Irinotecan?
Irinotecan, the active ingredient in Onivyde, is a topoisomerase I inhibitor presented as a liposomal formulation for intravenous use. It is employed in the treatment of metastatic colorectal cancer and is administered under the supervision of oncology specialists. GNH USA supplies Onivyde as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.
GNH USA supplies Onivyde as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.
What is Irinotecan used for?
Onivyde is a liposomal irinotecan formulation that targets cancers that rely on topoisomerase I activity.
- Metastatic colorectal cancer: improves the overall response to standard chemotherapy regimens. - Pancreatic adenocarcinoma: used in combination with fluorouracil‑based regimens for patients who have progressed after gem gem gem the . - Advanced . - . - .
What are the side effects of Irinotecan?
The
